Company intelligence / Profile preview
Stuart Therapeutics
Stuart, Florida, United Statesstuarttherapeutics.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
The company’s lead candidate ST‑100 completed a successful Phase II trial in dry eye disease. The study met its primary endpoint with statistically significant improvement in Schirmer’s Test Responder Rate at day 28 and showed improvements in ocular discomfort as early as day 14. Additional programs are at earlier stages targeting other ophthalmic diseases.
- Therapeutic areas
- Ophthalmology
- Modalities
- Synthetic proteins (Collagen Mimetic Peptides)Peptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on Stuart Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stuart Therapeutics.